Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Has announcements × RAD1901 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 36 Carboplatin 29 Cisplatin 26 Paclitaxel 22 Nivolumab 20 Pemetrexed 19 Gemcitabine 16 Dexamethasone 15 Ipilimumab 15 Docetaxel 11 Fluorouracil 11 Rituximab 11 Capecitabine 10 Cyclophosphamide 10 trastuzumab deruxtecan 9 130-nm albumin-bound paclitaxel 8 Cytarabine 8 Prednisone 8 Trastuzumab 8 atezolizumab 8 durvalumab 8 olaparib 8 Bevacizumab 7 Etoposide 7 Lenalidomide 7 Sunitinib 7 cabozantinib 7 daratumumab 7 zanubrutinib 7 Albumin-Bound Paclitaxel 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡